Clinical trial
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in…
NCT00175916 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00175916 |
|---|---|
| Title | Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy |
| Official title | An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Epilepsy |
| Intervention type | Drug |
| Interventions | Brivaracetam (ucb 34714) |
| Enrollment | 853 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2019 |
| Completion | May 1, 2019 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 17, 2021 |
| Countries | Austria, Belgium, Canada, Czechia, Finland, France, Germany, Hong Kong, Hungary, Israel, Italy, Netherlands and 14 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: